Ambit Biosciences Gets $6.4M In Debt

San Diego-based Ambit Biosciences, a developer of small molecule profiling tools being used for biopharmaceuticals development, has raised $6.5M in an ongoing, debt round, according to a filing from the firm today. Details on the debt round were not released by the company, however, according to the firm's filing, it is raising up to $19.7M in debt, including warrants in the firm. Ambit has raised over $105M in venture funding, from firms such as Apposite Capital, MedImmune, OrbiMed, Radius Ventures, NovaQuest, Horizon Technology Finance, Avalon Ventures, Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Roche Venture Fund, Lumira Capital, GIMV, Genechem Management, and Bristol-Myers Squibb.